Skip to main content
Doctor Kim Bull

Dr Kim Bull

 PhD, MSc, BSc (Hons)
Associate Professor

Research interests

  • Quality of survival in children treated for brain tumours within the context of European treatment trials.
  • Health-related quality of life in children treated for brain tumours.
  • Optomising the collection of patient-reported outcomes (PROs) in children treated for brain tumours.

More research


Dr Bull is a lecturer in the academic unit of Clinical and Experimental Sciences (CES).  She has several roles within the Faculty of Medicine.  She is the Psychology subject lead, coordinating the teaching of psychology to undergraduate medical students in the BM4/5/6/EU programmes.  She is the Foundations of Medicine deputy module lead, organising and coordinating the Foundations of Medicine tutorials during the first semester in year 1 of the BM5/6/EU programme.  She is the CES Academic Unit Coordinator for the BM5/6/EU Project Group which organises and coordinates the Research Project Module which takes place in year 3 in the BM5/6/EU programme.  She is also Head of Field for Paediatric Clinical Neurosciences BM5/6 year 3 projects.  She is a reviewer on the Faculty of Medicine ethics committee, representing CES. With regard to research, Dr Bull is co-investigator and Quality of Survival (QoS) lead for the CRUK funded International Society of Paediatric Oncology Europe (SIOPE) randomised controlled trial (RCT), ‘International prospective study on clinically high-risk medulloblastoma’ the commonest malignant brain tumour of childhood.  She is also co-investigator and the international and UK national QoS coordinator (funded by The Brain Tumour Charity) for SIOPE PNET5, the current European RCT for standard risk medulloblastoma. Dr Bull is also co-investigator on a Children with Cancer UK funded study entitled, ‘SMILE: An international network for medulloblastoma survivorship and late effects’, comprising a unique multidisciplinary team of internationally-leading experts and future leaders, optimally positioned to initiate a pan-European network for the development and delivery of future clinical advances in survivorship outcomes.